LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Hahn joined the new gas command unit at Imperial Headquarters in Berlin in December 1916 after travelling between the western and eastern front, Berlin and Leverkusen between mid-1914 and late 1916. Most of the students, laboratory assistants and technicians had been called up, so Hahn, who was stationed in Berlin between January and September 1917, and Meitner had to do everything themselves. By December 1917 she was able to isolate the substance, and after further work were able to prove that it was indeed the missing isotope. Meitner submitted her and Hahn's findings for publication in March 1918 to the scientific paper Physikalischen Zeitschrift under the title Die Muttersubstanz des Actiniums; Ein Neues Radioaktives Element von Langer Lebensdauer ("The Mother Substance of Actinium; A New Radioactive Element with a Long Lifetime"). Although Fajans and Göhring had been the first to discover the element, custom required that an element was represented by its longest-lived and most abundant isotope, and while brevium had a half-life of 1.7 minutes, Hahn and Meitner's isotope had one of 32,500 years. The name brevium no longer seemed appropriate. Fajans agreed to Meitner and Hahn naming the element "protoactinium". In June 1918, Soddy and John Cranston announced that they had extracted a sample of the isotope, but unlike Hahn and Meitner were unable to describe its characteristics. They acknowledged Hahn´s and Meitner's priority, and agreed to the name. The connection to uranium remained a mystery, as neither of the known isotopes of uranium decayed into protactinium.
== Bibliography == Ackerman, A. Bernard; Almut Böer; Bruce Bennin; Geoffrey J. Gottlieb (2005). Histologic Diagnosis of Inflammatory Skin Diseases An Algorithmic Method Based on Pattern Analysis. Ardor Scribendi. ISBN 978-1-893357-25-9. Archived from the original on 21 April 2011. Moore, Keith L. et al. (2010) Clinically Oriented Anatomy 6th Ed
=== Repetitions and sets === In strength training, an exercise is commonly performed several times in a row. Each performance is known as a repetition. Two or more repetitions make a set. For each repetition, a person moves through one or more stages of movement. This may involve an eccentric phase where a muscle lengthens, and a concentric phase where it shortens. Each phase is preceded by a preparatory and preloading phase, and followed by a recovery phase. For example, someone doing a press up exercise will position themselves on their hands and feet with their body straight. They then begin a repetition: they prepare to lower themselves, then they bend their arms and lower themselves (called the eccentric phase due to the lengthening of the triceps), they then stop themselves close to the floor and recover their energy- the recovery may be very briefly performed or may take longer depending on how tired they are. They then prepare to raise themselves making whatever adjustments to their position as they feel are needed and preloading themselves in terms of energy, they then straighten their arms and raise themselves (the concentric phase), and at the top of the movement they stop and recover- the recovery in this position is significantly greater than in the lower position. The repetition cycle is then repeated beginning with a new preparatory phase. For different exercises the cycle may alter but will always contain preparatory and recovery phases. Sets may also be performed multiple times with rest periods between them.
== Further reading == David A. Epstein, Left, Right, Out: The History of Third Parties in America. Arts and Letters Imperium Publications. 2008. Alan Feuer, "Inside Socialist Party Headquarters". The New York Times. October 20, 2008. R. W. Tucker, "The Debs Caucus: A Party Within a Party". Madison, WI. Socialist Party of Wisconsin. December 1970.
=== Bacterial sensitivity === The fosfomycin molecule has an epoxide or oxirane ring, which is highly strained and thus very reactive. Fosfomycin has broad antibacterial activity against both Gram-positive and Gram-negative pathogens, with useful activity against E. faecalis, E. coli, and various Gram-negatives such as Citrobacter and Proteus. Given a greater activity in a low-pH milieu, and predominant excretion in active form into the urine, fosfomycin has found use for the prophylaxis and treatment of UTIs caused by these uropathogens. Of note, activity against S. saprophyticus, Klebsiella, and Enterobacter is variable and should be confirmed by minimum inhibitory concentration testing. Activity against extended-spectrum β-lactamase-producing pathogens, notably ESBL-producing E. coli, is good to excellent, because the drug is not affected by cross-resistance issues. Existing clinical data support use in uncomplicated UTIs, caused by susceptible organisms. However, susceptibility break-points of 64 mg/L should not be applied for systemic infections.
Sources: en.wikipedia.org
Ribosomal RNA (rRNA) is the catalytic component of the ribosomes. The rRNA is the component of the ribosome that hosts translation. Eukaryotic ribosomes contain four different rRNA molecules: 18S, 5.8S, 28S and 5S rRNA. Three of the rRNA molecules are synthesized in the nucleolus, and one is synthesized elsewhere. In the cytoplasm, ribosomal RNA and protein combine to form a nucleoprotein called a ribosome. The ribosome binds mRNA and carries out protein synthesis. Several ribosomes may be attached to a single mRNA at any time. Nearly all the RNA found in a typical eukaryotic cell is rRNA. Transfer-messenger RNA (tmRNA) is found in many bacteria and plastids. It tags proteins encoded by mRNAs that lack stop codons for degradation and prevents the ribosome from stalling.
=== Dihydrolipoyl dehydrogenase (E3) === The dihydrolipoate, covalently bound to a lysine residue of the complex, is then transferred to the Dihydrolipoyl dehydrogenase (E3) active site, where it undergoes a flavin-mediated oxidation, similar in chemistry to e.g. thioredoxin reductase. First, FAD oxidizes dihydrolipoate back to its lipoate (disulfide) resting state, producing FADH2. Then, the substrate NAD+ oxidizes FADH2 back to its FAD resting state, producing NADH and H+.
== Medical uses == Butizide is used in combination with the potassium-sparing diuretic spironolactone for the second-line treatment of edema caused by heart failure, and for difficult cases of hypertension.
=== History of thalassemia === Rudolf Von Jaksch in 1889 first described "anaemia leucaemic infantum" as a form of chronic anemia in children which combined with an enlarged spleen, and abnormal size and shape of the red blood cells. His discovery was subsequently found to comprise a collection of different conditions. The first definitive identification of a thalassemia was in 1925 by Thomas Benton Cooley, an American pediatrician specialising in hematology and childhood anemias. Cooley noted similarities in symptoms of children in his care having Greek or Italian ancestry; he named it "erythroblastic anemia," but it became popularly known as Cooley's anemia (now termed beta thalassemia major). The term "thalassemia" was coined by George Whipple in 1932. The word "thalassemia" comes from the Greek word thalassa, which means "sea". The suffix "-emia" comes from the Greek word haima, which means "blood". The term was coined because the condition was strongly associated with people of Mediterranean descent. In 1948, Italian researchers established that the type of thalassemia which was prevalent in Italy was inherited in a recessive pattern.
Sources: en.wikipedia.org
United States government sanctions are financial and trade restrictions imposed against individuals, entities, and jurisdictions whose actions contradict U.S. foreign policy or national security goals. Financial sanctions are primarily administered by the U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC), while export controls are primarily administered by the U.S. Department of Commerce's Bureau of Industry and Security (BIS). Restrictions against sanctioned targets vary in severity. Comprehensive sanctions currently target Cuba, Iran, North Korea, Russia, and certain conflict regions of Ukraine, heavily restricting nearly all trade and financial transactions between U.S. persons and those regions. Targeted sanctions focus on specific individuals or entities engaged in activities contrary to U.S. foreign policy or national security goals. The U.S. also implements "secondary sanctions," which risk a sanctions designation against a non-U.S. person who transacts with sanctioned parties in violation of U.S. sanctions law, even where no U.S.-jurisdictional nexus existed. Critics of the United States sanctions program raise humanitarian concerns related to adverse impacts felt by populations whose governments or economies have been sanctioned, as well as cases where sanctions were not effective in deterring adversarial activities.
=== International and Enterprise divisions === UPMC's International and Commercial Services Division (ICSD) actively manages UPMC's for-profit companies that seek to commercialize its expertise in health care, advanced technologies, and management skills to global markets. Its stated goal is "to advance UPMC's mission of positively transforming the way health care is provided in the U.S. and abroad, while revitalizing the economy of western Pennsylvania." UPMC International provides health care consulting and management services around the world in areas in various areas including clinical program development, facility and construction planning, clinical investigation, clinical and administrative staff training, and health information technology, and quality, safety, and Innovation. UPMC Enterprises is an innovation and commercialization arm of UPMC which has invested over $700 million in about 80 different ventures in the past twenty years. It seeks to create products and business arising from translational science and technology solutions by collaborating with entrepreneurs. In the past, it has also forged collaborations with companies such as dbMotion) and strategic and commercial product development partnerships with companies such as IBM and Alcatel-Lucent. UPMC Enterprises portfolio includes such companies as ALung, and Prodiogo Solutions.
== History and chemistry == Diphenoxylate was first synthesized by Paul Janssen at Janssen Pharmaceutica in 1956 as part of a medicinal chemistry investigation of opioids. Diphenoxylate is made by combining a precursor of normethadone with norpethidine. Loperamide (Imodium) and bezitramide are analogs. Like loperamide, it has a methadone-like structure and a piperidine moiety.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.